{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:45:05Z","timestamp":1791510305057,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.1038\/s41416-021-01624-2","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T09:03:09Z","timestamp":1637571789000},"page":"440-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials"],"prefix":"10.1038","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-9917","authenticated-orcid":false,"given":"Daniel","family":"Pietrasz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Wang-Renault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Postel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Durand-Labrunie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mulot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Phelip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solene","family":"Doat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Blons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelien","family":"de Reynies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-8602","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Taly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-5459","authenticated-orcid":false,"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"1624_CR1","doi-asserted-by":"crossref","unstructured":"Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2020;126:2225\u201349.","DOI":"10.1002\/cncr.32802"},{"key":"1624_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin."},{"key":"1624_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med."},{"key":"1624_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med."},{"key":"1624_CR5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"1624_CR6","first-page":"340","volume":"13","author":"KE Poruk","year":"2013","unstructured":"Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13:340\u201351.","journal-title":"Curr Mol Med."},{"key":"1624_CR7","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379:1754\u201365.","journal-title":"N Engl J Med."},{"key":"1624_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1373\/clinchem.2017.283721","volume":"64","author":"MK Kim","year":"2018","unstructured":"Kim MK, Woo SM, Park B, Yoon K-A, Kim Y-H, Joo J, et al. Prognostic implications of multiplex detection of KRAS mutations in cell-free DNA from patients with pancreatic ductal adenocarcinoma. Clin Chem. 2018;64:726\u201334.","journal-title":"Clin Chem."},{"key":"1624_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.gene.2018.09.029","volume":"679","author":"L Chen","year":"2018","unstructured":"Chen L, Zhang Y, Cheng Y, Zhang D, Zhu S, Ma X. Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: a systemic review and meta-analysis. Gene. 2018;679:328\u201334.","journal-title":"Gene."},{"key":"1624_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/ijc.32586","volume":"146","author":"M Strijker","year":"2020","unstructured":"Strijker M, Soer EC, de Pastena M, Creemers A, Balduzzi A, Beagan JJ, et al. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Int J Cancer. 2020;146:1445\u201356.","journal-title":"Int J Cancer."},{"key":"1624_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cas.14245","volume":"111","author":"M Sugimori","year":"2020","unstructured":"Sugimori M, Sugimori K, Tsuchiya H, Suzuki Y, Tsuyuki S, Kaneta Y, et al. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Sci. 2020;111:266\u201378.","journal-title":"Cancer Sci"},{"key":"1624_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/1078-0432.CCR-16-0806","volume":"23","author":"D Pietrasz","year":"2017","unstructured":"Pietrasz D, P\u00e9cuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res. 2017;23:116\u201323.","journal-title":"Clin Cancer Res."},{"key":"1624_CR13","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1200\/JCO.2018.36.15_suppl.4000","volume":"36","author":"L Dahan","year":"2018","unstructured":"Dahan L, Phelip JM, Le Malicot K, Williet N, Desrame J, Volet J, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35-PANOPTIMOX). J Clin Oncol Am Soc Clin Oncol. 2018;36:4000\u20134000.","journal-title":"J Clin Oncol Am Soc Clin Oncol"},{"key":"1624_CR14","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.2018.36.15_suppl.4107","volume":"36","author":"J Taieb","year":"2018","unstructured":"Taieb J, Rinaldi Y, Pointet A-L, Barbier E, Khemissa F, Gratet A, et al. gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX). J Clin Oncol Am Soc Clin Oncol. 2018;36:4107\u20134107.","journal-title":"J Clin Oncol Am Soc Clin Oncol"},{"key":"1624_CR15","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/clinchem\/hvaa125","volume":"66","author":"JF Huggett","year":"2020","unstructured":"dMIQE Group, Huggett JF. The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020. Clin Chem. 2020;66:1012\u201329.","journal-title":"Clin Chem."},{"key":"1624_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.gastro.2018.09.022","volume":"156","author":"V Bernard","year":"2019","unstructured":"Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 2019;156:108\u2013118.e4.","journal-title":"Gastroenterology."},{"key":"1624_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3109\/07357907.2014.1001894","volume":"33","author":"N Singh","year":"2015","unstructured":"Singh N, Gupta S, Pandey RM, Chauhan SS, Saraya A. High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival. Cancer Invest. 2015;33:78\u201385.","journal-title":"Cancer Invest"},{"key":"1624_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1634\/theoncologist.2017-0467","volume":"23","author":"R Perets","year":"2018","unstructured":"Perets R, Greenberg O, Shentzer T, Semenisty V, Epelbaum R, Bick T, et al. Mutant KRAS circulating tumor DNA is an accurate tool for pancreatic cancer monitoring. Oncologist. 2018;23:566\u201372.","journal-title":"Oncologist."},{"key":"1624_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/bjc.2016.175","volume":"115","author":"N Hadano","year":"2016","unstructured":"Hadano N, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N, et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016;115:59\u201365.","journal-title":"Br J Cancer."},{"key":"1624_CR20","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3389\/fonc.2019.01295","volume":"9","author":"Z-Y Wang","year":"2019","unstructured":"Wang Z-Y, Ding X-Q, Zhu H, Wang R-X, Pan X-R, Tong J-H. KRAS mutant allele fraction in circulating cell-free DNA correlates with clinical stage in pancreatic cancer patients. Front Oncol. 2019;9:1295.","journal-title":"Front Oncol."},{"key":"1624_CR21","doi-asserted-by":"publisher","first-page":"e0235623","DOI":"10.1371\/journal.pone.0235623","volume":"15","author":"Y Uesato","year":"2020","unstructured":"Uesato Y, Sasahira N, Ozaka M, Sasaki T, Takatsuki M, Zembutsu H. Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis. PLoS ONE. 2020;15:e0235623.","journal-title":"PLoS ONE."},{"key":"1624_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1779-7","volume":"15","author":"J Earl","year":"2015","unstructured":"Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodr\u00edguez-Garrote M, et al. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015;15:797.","journal-title":"BMC Cancer"},{"key":"1624_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08297-z","volume":"7","author":"ReM Del","year":"2017","unstructured":"Del ReM, Vivaldi C, Rofi E, Vasile E, Miccoli M, Caparello C, et al. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci Rep. 2017;7:7931.","journal-title":"Sci Rep."},{"key":"1624_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14737159.2018.1400384","volume":"18","author":"M Postel","year":"2018","unstructured":"Postel M, Roosen A, Laurent-Puig P, Taly V, Wang-Renault S-F. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev Mol Diagn. 2018;18:7\u201317.","journal-title":"Expert Rev Mol Diagn."},{"key":"1624_CR25","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47:D941\u20137.","journal-title":"Nucleic Acids Res."},{"key":"1624_CR26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1373\/clinchem.2015.253609","volume":"62","author":"S Garrigou","year":"2016","unstructured":"Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, et al. A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem. 2016;62:1129\u201339.","journal-title":"Clin Chem."},{"key":"1624_CR27","doi-asserted-by":"crossref","unstructured":"Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357:eaal2380.","DOI":"10.1126\/science.aal2380"},{"key":"1624_CR28","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1136\/gutjnl-2016-313372","volume":"67","author":"L Barault","year":"2018","unstructured":"Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2018;67:1995\u20132005.","journal-title":"Gut."},{"key":"1624_CR29","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nmat4997","volume":"16","author":"R-H Xu","year":"2017","unstructured":"Xu R-H, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16:1155\u201361.","journal-title":"Nat Mater."},{"key":"1624_CR30","doi-asserted-by":"publisher","unstructured":"Brancaccio M, Natale F, Falco G, Angrisano T. Cell-free DNA methylation: the new frontiers of pancreatic cancer biomarkers\u2019 discovery. Genes. https:\/\/doi.org\/10.3390\/genes11010014. 2019;11:14.","DOI":"10.3390\/genes11010014"},{"key":"1624_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cca.2018.01.024","volume":"479","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients. Clin Chim Acta. 2018;479:181\u20139.","journal-title":"Clin Chim Acta."},{"key":"1624_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-019-0824-4","volume":"12","author":"H Patel","year":"2019","unstructured":"Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, et al. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130.","journal-title":"J Hematol Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01624-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T10:12:04Z","timestamp":1643796724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01624-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,1]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01624-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JT has received honoraria for speaker or advisory roles from AMGEN, Roche, MERCKKGaA, MSD, Lilly, Servier, Sanofi, Pierre Fabre, AstraZeneca, Samsung Bioepis, HallioDx. JBB has received personal fees from Amgen, AstraZeneca, Bayer, Merck Serono, Pierre Fabre, Roche, Sanofi, Servier, Shire, and non-financial support from Amgen, Merck Serono, and Roche. PLP declares consulting for or personal fees from Amgen, AstraZeneca, Biocartis, BMS, Boehringer-Ingelheim, Lilly, Merck Serono, MSD, Sanofi, Servier, Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the patients included in the PLAPAN cohort signed an informed consent form approved by the ethics committee (CPP Ile-de-France 2014\/59NICB). PRODIGE 35 PANOPTIMOX trial (NCT02352337) PRODIGE 37 FIRGEMAX (NCT 02827201) trials were approved by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}